The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults aged ≥70 years with acute myeloid leukemia. However, although potentially curative, nonrelapse mortality and relapse represent the main causes of treatment failure, highlighting the importance of refining both patient selection and transplant strategies. At the same time, continuously evolving nontransplant therapies and transplant technologies mandate prospective trials (re-)examining the role of allo-HCT and its optimal delivery.

中文翻译：

---

同种异体造血细胞移植治疗 70 岁以上成人急性髓性白血病


低强度预处理方案的出现、移植物抗宿主病预防的改进以及更好的支持性护理，使得在 ≥ 70 岁的急性髓性白血病成人患者中越来越多地使用同种异体造血细胞移植 （allogeneic hematopoietic cell transplantation， allo-HCT）。然而，尽管可能治愈，但非复发死亡率和复发是治疗失败的主要原因，这凸显了改进患者选择和移植策略的重要性。与此同时，不断发展的非移植疗法和移植技术要求前瞻性试验（重新）检查同种异体 HCT 的作用及其最佳递送。